DUBLIN, March 31, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a fireside chat at the Jones Healthcare and Technology Innovation Conference in Las Vegas on ...

“During 2024 and Q1 2025, we made significant progress shaping the company for success,” said Daniel Passeri, chief executive officer of Cue Biopharma (CUE). “We believe that the ongoing ...

TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma ” or the “Company ”) is pleased to announce that it has closed ...

SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect” or the “Company”), a ...

The finalists for the biopharma track of INVEST Pitch Perfect have been selected. At the INVEST Pitch Perfect boutique healthcare investor conference, six biopharma companies will present their ...

On Tuesday, Bernstein released a report detailing the complexities of tariff risks within the biopharma sector and its potential impact on major companies. The analysis aims to unravel the ...

At least 63 biopharma layoff rounds were conducted in the first quarter of this year, with cell and gene biotechs accounting for nearly a third of those rounds. The cuts were accompanied by eight ...

But the promise of AI in biopharma is equally tempered by the long journey ahead and the technology’s many uncertainties. For this year’s State of Tech in Biopharma report, we were deeply ...

Equities research analysts at Redburn Atlantic began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a research note issued on Monday, Marketbeat.com reports.

Life-changing interventions that have previously been pipedreams are now within reach for the biopharma industry, made possible through an increasingly sophisticated understanding of human biology ...

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last issued its quarterly earnings data on Thursday, February 20th.The company reported ($1.31) EPS for the quarter, missing the consensus ...